Our methods of clinical examination, diagnosis, and treatment have been described previously.1 In this study, we recorded patient details at presentation, including age, race, sex, medical history (hypertension, diabetes mellitus, hypercholesterolemia, dysplastic nevus syndrome, and skin melanoma), and family history (choroidal or skin melanoma). The general ocular details included patient symptoms, visual acuity, anterior segment details, and intraocular pressure. Specific tumor details included quadrant of tumor epicenter, number of clock-hours the tumor encompassed the optic nerve, distance in millimeters to the optic disc, percentage overhang of the optic disc by the tumor, distance to the foveola in millimeters, largest basal diameter in millimeters, thickness in millimeters, tumor shape, growth pattern (dome, mushroom, or diffuse), color (pigmented, partially pigmented, or nonpigmented), extraocular extension, retinal invasion, subretinal fluid, orange pigment, optic disc swelling, and retinal vascular congestion. The plaque radiotherapy details included information on radioactive isotope (iodine 125 or cobalt 60), shape (round, notched, or rectangular), distribution (full or posterior), time of radiation exposure (hours), and radiation dosage and rates to the tumor apex, tumor base, optic disc, foveola, and lens. Additional treatment details included the number of sessions of adjunctive transpupillary thermotherapy (TTT) and treatment strategy, adjunctive argon laser photocoagulation or krypton laser photocoagulation. Patients who had TTT or adjunctive argon laser photocoagulation/krypton laser photocoagulation as a primary treatment before plaque radiotherapy and those who had adjunctive argon laser photocoagulation as planned adjunctive treatment following plaque radiotherapy were excluded from the outcomes analysis. Follow-up data included radiation complications (nonproliferative and proliferative radiation retinopathy, maculopathy, papillopathy, radiation cataract, neovascular glaucoma, vitreous hemorrhage, and scleral necrosis), thermotherapy complications (venous or arterial occlusion, thermal damage to optic nerve), final visual acuity of 20/200 or worse, visual loss of more than 5 Snellen lines, need for enucleation, and recurrence of tumor (any evidence of tumor regrowth). Outcomes of systemic metastasis (judged by clinical examination, liver function serology, and chest and liver imaging) and deaths from metastatic disease were also recorded.